Showing 15 posts of 46 posts found.

Pfizer’s Lyrica achieves endpoint as adjunct in paediatric epilepsy

May 18, 2018
Medical Communications, Research and Development FDA, Lyrica, Pfizer, epilepsy, pharma

Pfizer has revealed new Phase 3 data for its oral epilepsy therapy Lyrica (pregbalin) as an adjunctive treatment for partial …

MHRA bans sodium valproate in the UK following birth defect controversy

April 24, 2018
Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi, Sodium valproate, bipolar, epilepsy, pharma

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced that sodium valproate, a drug used in the treatment …


Antiepileptic drug use linked to increased risk of Alzheimer’s and dementia

April 10, 2018
Manufacturing and Production, Research and Development Alzheimer's disease, dementia, epilepsy, pharma

A new study conducted at the University of Eastern Finland and the German Center for Neurodegenerative Diseases (DZNE) has revealed …


Real-world data prove efficacy of Eisai and Bial’s epilepsy treatment

September 6, 2017
Research and Development Bial, Eisai, Zebinix, epilepsy, pharma

Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset …


Cannabidiol drug found to aid in devastating childhood epilepsy condition

May 25, 2017
Research and Development GW Pharmaceuticals, cannabidoil, epilepsy

A treatment derived from cannabis has been found to produce remarkable results in children who have epilepsy. Cannabidoil, when offered …

European approval for novel Eisai epilepsy monotherapy

May 23, 2017
Research and Development, Sales and Marketing Bial, Eisai, Zebinix, epilepsy

Eisai and Bial have revealed that their drug Zebinix (eslicarbazepine acetate) has been awarded marketing authorisation by the European Commission …


Love it or hate it – Vitamin B12 may give the brain a boost

April 13, 2017
Research and Development Marmite, anxiety, epilepsy

Trying to explain to someone outside of the UK or Australia and New Zealand what Marmite is can be a …


Eisai reveals new long-term seizure control data at ECE 2016

September 13, 2016
Manufacturing and Production, Research and Development Eisai, epilepsy

Eisai has revealed new data on long-term seizure control in different seizure types at the 12th European Congress on Epileptology …


GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA

April 21, 2016
Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy

GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …


Pfizer fined for epilepsy drug price increase by UK antitrust regulator

April 15, 2016
Medical Communications CMA, Flynn Pharma, Pfizer, antitrust, competition and markets authority, epilepsy, fine, flynn

Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and …


New epilepsy drug launches in UK

February 29, 2016
Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015
Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …

Sun Pharma logo

FDA withdraws approval for Sun Pharma’s epilepsy drug

September 29, 2015
Manufacturing and Production Elepsia, FDA, Sun Pharma, epilepsy, levetiracetam, manufacturing, productions, seizures

Manufacturing problems at Sun Pharma’s production site has led the FDA to revoke the company’s approval for Elepsia XR for …


High Court rules against Pfizer in Lyrica patent case

September 10, 2015
Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, anxiety, epilepsy, generics, neuropathic pain, pregabalin

The High Court of England and Wales today ruled against Pfizer in the patent battle with Actavis on Pfizer’s blockbuster …

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

August 6, 2015
Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing

Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …

Latest content